Explore the full record of transactions filed by René Holecek personne liée à Ondej Novák, Shareholder. Insider active across 1 companies, notably CLARIANE SE. Cumulatively, 3 disclosures have been published. The latest transaction was filed on 5 July 2024 (Souscription). Regulator: AMF. The full history is openly available.
3 of 3 declarations
René Holecek is best described as a Czech industrial investor, entrepreneur and philanthropist with a direct connection to Clariane SE through his family investment vehicle, Leima Valeurs. Clariane’s public governance and capital-markets disclosures identify Leima Valeurs as Mr. René Holeček’s investment fund and note that he is also the majority shareholder of Colt CZ Group SE, a Prague-listed industrial company. In Clariane’s shareholder and market disclosures, his name appears in connection with capital increase subscriptions and subsequent shareholding adjustments in 2024, showing that he has played an active role in the company’s shareholder structure. His profile is characterized by a long-term, industrial style of capital allocation rather than day-to-day management. Public documentation indicates that he invests beyond his core business into healthcare, including early-stage pharmaceutical and biotechnology research. That makes his involvement particularly relevant for a healthcare group such as Clariane, whose business spans long-term care, rehabilitation, mental health services and support for vulnerable people across Europe. In this context, Holecek’s value lies primarily in strategic support, capital strength and alignment with a healthcare-oriented investment thesis. The public record also highlights the family-office dimension of his investment platform. Leima Valeurs is described as an entity controlled at the highest level by Mr. Holeček, which suggests a structured and patient approach to ownership. In 2024, his involvement in Clariane’s capital strengthening process showed the ability to commit substantial resources to a listed company undergoing financial reinforcement. More broadly, his background combines industrial ownership, international investment experience and a clear interest in health-related innovation. For a listed group like Clariane, that mix is especially valuable because it aligns patient capital with a sector requiring stability, credibility and a long investment horizon.